Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe

Oncotelic Therapeutics, Inc.

Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.
Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.
Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.
Sapu Nano seeking strategic partnerships to accelerate development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.